Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
17-2-1|n/a,n/a|Sequence:1, Age:n/a,Type:X-rays whole body,Quantity:11.7,Unit:grays,Application:External exposure, Remarks:300 kV|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-1|n/a,n/a|Sequence:2, Age:n/a,Type:allogenic Bone marrow transplant,Quantity:,Unit:millions of cells injected,Application:Injection, intravenous, Remarks:allogenic 0.39-2.76 billion mononuclear and 2000-191000 GM-CFC cells|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-2|n/a,n/a|Sequence:1, Age:n/a,Type:X-rays whole body,Quantity:11.7,Unit:grays,Application:External exposure, Remarks:300 kV|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-2|n/a,n/a|Sequence:2, Age:n/a,Type:allogenic Bone marrow transplant,Quantity:,Unit:millions of cells injected,Application:Injection, intravenous, Remarks:allogenic 0.51-1.87 billion mononuclear and 7000-142000 GM-CFC cells|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-2|n/a,n/a|Sequence:3, Age:n/a,Type:methotrexate,Quantity:0.25,Unit:milligrams per kg animal,Application:not applicable or not supplied, Remarks:on d 1,3,6, from d11 0.5 mg/kg weekly for 100d|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-3|n/a,n/a|Sequence:1, Age:n/a,Type:X-rays whole body,Quantity:11.7,Unit:grays,Application:External exposure, Remarks:300 kV|2 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-3|n/a,n/a|Sequence:2, Age:n/a,Type:allogenic Bone marrow transplant,Quantity:,Unit:millions of cells injected,Application:Injection, intravenous, Remarks:allogenic partially heterozyogous 0.68/0.73 billion mononuclear and 68000/73000 GM-CFC cells|2 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-3|n/a,n/a|Sequence:3, Age:n/a,Type:methotrexate,Quantity:0.25,Unit:milligrams per kg animal,Application:not applicable or not supplied, Remarks:on d 1,3,6, from d11 0.5 mg/kg weekly for 100d|2 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
		
